COVID-19 outcomes in patients with multiple sclerosis: understanding changes from 2020 to 2022
- Type de publi. : Article dans une revue
- Date de publi. : 01/03/2024
-
Auteurs :
Lina JeantinEdouard JanuelPierre LabaugeElisabeth MaillartJérôme de SèzeHélène ZéphirJean PelletierPhilippe KerschenDamien BiottiOlivier HeinzlefLaurent GuillotonCaroline BensaMarie ThéaudinSandra VukusicOlivier CasezAude MauroussetDavid-Axel LaplaudEric BergerChristine Lebrun-FrénayBertrand BourrePierre BrangerBruno StankoffPierre ClavelouEric ThouvenotEric ManchonThibault MoreauFrançois SellalMickaël ZedetCaroline PapeixCéline Louapre
-
Organismes :
Institut du Cerveau = Paris Brain Institute
Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière]
Institut du Cerveau = Paris Brain Institute
Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière]
Institut Pierre Louis d'Epidémiologie et de Santé Publique
Institut des Neurosciences de Montpellier
Institut du Cerveau = Paris Brain Institute
Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière]
CIC Strasbourg
Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837
Centre Hospitalier Régional Universitaire [CHU Lille]
Service de neurophysiologie clinique [Hôpital de la Timone - APHM]
Hôpital Kirchberg [Luxembourg]
Institut Toulousain des Maladies Infectieuses et Inflammatoires
Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy]
Association des Neurologues Libéraux de Langue Française
Service de neurologie [Hôpital Fondation Adolphe de Rothschild]
Université de Lausanne = University of Lausanne
Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL]
Centre Hospitalier Universitaire [CHU Grenoble]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
Team 5 : Neuroinflammation, mechanisms, therapeutic options (NEMO)
CHU Rouen
Service de Neurologie [CHU Caen]
CHU Saint-Antoine [AP-HP]
CHU Clermont-Ferrand
Institut de Génomique Fonctionnelle
Université de Strasbourg
CHU Henri Mondor [Créteil]
Service de neurologie [Hôpital Fondation Adolphe de Rothschild]
Institut du Cerveau = Paris Brain Institute
Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière]
- Publié dans Multiple Sclerosis Journal le 31/10/2020
Résumé : Background: Epidemiologic studies on coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (pwMS) have focused on the first waves of the pandemic until early 2021. Objectives: We aimed to extend these data from the onset of the pandemic to the global coverage by vaccination in summer 2022. Methods: This retrospective, multicenter observational study analyzed COVISEP registry data on reported COVID-19 cases in pwMS between January 2020 and July 2022. Severe COVID-19 was defined as hospitalization or higher severity. Results: Among 2584 pwMS with confirmed/highly suspected COVID-19, severe infection rates declined from 14.6% preomicron wave to 5.7% during omicron wave ( p < 0.001). Multivariate analysis identified age (odds ratio (OR) = 1.43, 95% confidence interval (CI) = [1.25–1.64] per 10 years), male sex (OR = 2.01, 95% CI = [1.51–2.67]), obesity (OR = 2.36, 95% CI = [1.52–3.68]), cardiac comorbidities (OR = 2.36, 95% CI = [1.46–3.83]), higher Expanded Disability Status Scale (EDSS) scores (OR = 2.09, 95% CI = [1.43–3.06] for EDSS 3–5.5 and OR = 4.53, 95% CI = [3.04–6.75] for EDSS ⩾6), and anti-CD20 therapies (OR = 2.67, 95% CI = [1.85–3.87]) as risk factors for COVID-19 severity. Vaccinated individuals experienced less severe COVID-19, whether on (risk ratio (RR) = 0.64, 95% CI = [0.60–0.69]) or off (RR = 0.32, 95% CI = [0.30–0.33]) anti-CD20. Discussion: In pwMS, consistent risk factors were anti-CD20 therapies and neurological disability, emerging as vital drivers of COVID-19 severity regardless of wave, period, or vaccination status.
Fichiers liés :
covisep_hal.pdf
Source